Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine
April 15, 2015 at 17:04 PM EDT
Celgene Corporation (NASDAQ: CELG) today announced that results from a multicenter, randomized, placebo-controlled phase II trial ...